Why the study?
Does benznidazole improve clinical condition and reduce parasitemia in patients with HIV and chronic Chagas' disease experiencing reactivation?
Does benznidazole improve clinical condition and reduce parasitemia in patients with HIV and chronic Chagas' disease experiencing reactivation?
In patients with HIV and chronic Chagas' disease, reactivation can cause cardiac disease, which may be effectively managed with benznidazole.
Benznidazole may improve outcomes in HIV-Chagas reactivation; leaves open efficacy in prospective trials.
A series of 18 patients with chronic Chagas' disease and human immunodeficiency virus infection were followed up for 2 to 66 months (median, 15.5 months). Artificial xenodiagnosis was positive for 81.3% and natural xenodiagnosis was positive for 81.8% of patients for whom they were performed; 81.8% of 11 patients had medium- or high-level parasitemia. Reactivation of Chagas' disease--direct microscopic examination of blood revealing parasites and, clinically, patients presenting with cardiac disease--occurred in three patients (16.7%). Specific antitrypanosomal treatment with benznidazole was effective in reducing the level of parasitemia and improving the clinical condition in three of the four patients treated.
No takes yet. Share an insight, caveat, or question.
Sartori et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: